June 2, 2025 | Vensana Capital® Portfolio News

SpyGlass Pharma Raises $75 Million Series D Funding to Advance Its Long-term Drug Delivery Platform for Glaucoma Patients

21

Novel FDA PMA & de novo 510k approvals

60

U.S. Commercial Product Launches

40

Level I Clinical Trials

32

Strategic Financings

31

Exits by IPO or M&A